The steady-state pharmacokinetics of ciprofloxacin were evaluated in nine elderly patients with lower respiratory tract infections after an intravenous dosage regimen of 200 mg every 12 h (n = 9) and an oral dosage regimen of 750 mg every 12 h (n = 6). Ciprofloxacin concentrations in serum and urine were measured by high-performance liquid chromatography. The peak concentration in serum, total body clearance (CLs), steady-state volume of distribution (V8,), and terminal elimination half-life after intravenous dosing were 3.5 + 0.8 ,ug/ml, 4.38 ± 1.80 ml/min per kg, 1.6 ± 0.6 liters/kg, and 5.8 ± 2.4 h, respectively. The peak concentration in serum, time to peak concentration in serum, absorption lag time, and absolute bioavailability (F) after oral dosing were 7.6 ± 2.2 ,Lg/ml, 1.9 ± 1.0 h, 0.4 ± 0.5 h, and 77.7 ± 24.2%, respectively. The elevated drug concentrations in serum samples from the elderly after oral dosing, compared with data obtained from younger subjects, appear to be a function of reduced CLs, renal clearance, and V,,. The increased F observed in some patients may be due to the effect of concomitant or proximate administration of tube feedings, medications which may alter gastric motility or acidity, or decreased first-pass metabolism. The results demonstrate that factors related to age and declining renal function, rather than infectious disease state, may be primary in determining alterations in pharmacokinetic parameters in the elderly. In elderly patients with normal renal function for their age, no dosage adjustment for intravenous or oral ciprofloxacin is necessary.
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Ciprofloxacin, a quinolone carboxylic acid derivative currently marketed in an oral dosage formulation and available as an investigational intravenous preparation, demonstrates in vitro activity against a broad spectrum of aerobic gramnegative and gram-positive bacteria, including strains resistant to aminoglycosides and beta-lactam antibiotics (6) . The drug penetrates well into most tissues and is used clinically in the treatment of a variety of infections, including pneumonia (6) .
The pharmacokinetics of ciprofloxacin have been characterized in adults with normal and impaired renal function after single and multiple dose administration (4, 5, 8, 9, 11, 13, 14, 16, 20) . Few investigators have compared the disposition of ciprofloxacin in elderly subjects and young volunteers. Ball et al. (2) reported significant increases in the peak ciprofloxacin concentration in serum and area under the serum-concentration-versus-time curve in elderly patients with mild urinary tract infections compared with young volunteers after a single 100-mg oral dose. In both groups, the mean terminal elimination half-lives were almost identical. Although the apparent volume of distribution or renal clearance was not reported, the pharmacokinetic differences were attributed to altered volume of distribution or increased bioavailability with aging. Similar conclusions were reported by Bayer et al. (3) . LeBel et al. (15) also reported significantly higher ciprofloxacin concentrations in serum but observed a twofold increase in the ciprofloxacin elimination half-life of healthy elderly subjects compared with that of young volunteers after a single 500-mg oral dose. These alterations were partially explained by a decreased glomerular filtration rate, as demonstrated by a lower renal clear-* Corresponding author.
ance of ciprofloxacin and a decreased apparent volume of distribution of the drug in elderly subjects.
In a multiple dose study in elderly patients with serious infections, Guay et al. (12) characterized the pharmacokinetics of oral ciprofloxacin (750 mg every 12 h) during first dose (acutely ill phase) and maintenance dose (convalescentphase) therapy. No significant differences were noted between the first dose and steady-state pharmacokinetic parameters, with the exception of an increase in the apparent volume of distribution. The results were consistent with previous studies in healthy and mildly ill elderly subjects undergoing assessment after single doses of oral ciprofloxacin in that the maximum concentration of drug in serum (Cmax) and area under the concentration-time curve (AUC) were increased compared with those of young volunteers receiving the same doses (2, 3, 5, 9, 11, 15) .
These studies suggest that the pharmacokinetics of ciprofloxacin are altered in elderly subjects. However, comparative intravenous and oral ciprofloxacin pharmacokinetic parameters during maintenance dose therapy in the elderly have not been evaluated. Therefore, this study was designed to evaluate the pharmacokinetics of ciprofloxacin at steady state after intravenous and oral dosing in elderly patients requiring initial hospitalization for lower respiratory tract infections and to assess currently utilized doses of intravenous and oral ciprofloxacin.
MATERIALS AND METHODS Patients. Nine elderly patients with moderate to severe lower respiratory tract infections warranting initial hospitalization and receiving ciprofloxacin therapy under clinical efficacy and safety investigational protocols were eligible for enrollment into the study. The protocol was approved by the Human Subjects Research Committee of Hennepin County Medical Center, and written, informed consent was granted by the patients or their legal guardians before enrollment into the study.
Drug administration. Of nine subjects assessed after receiving 200 mg of ciprofloxacin intravenously every 12 h, six were also assessed after receiving 750 mg orally every 12 h. Subjects were evaluated after receiving a minimum of five intravenous or oral doses. Sucralfate and antacids were discontinued for the duration of antibiotic therapy. On pharmacokinetic assessment days, ciprofloxacin was administered after an overnight fast when possible, and breakfast was delayed for at least 1 h.
Blood and urine sampling. For the intravenous pharmacokinetic assessment, the dose was administered over 1 h via a constant rate intravenous infusion pump (FlowGard 8000 [Baxter-Travenol, Deerfield, Ill.]). Blood samples were collected from an indwelling heparinized catheter in the contralateral arm into red-top VACUTAINER tubes (Becton Dickinson, Rutherford, N.J.) immediately before the dose, midway through the infusion, at the end of the infusion, and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 11 h after the end of the infusion. For the oral pharmacokinetic assessment, blood samples were collected immediately before dosing and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 h after dose administration. Samples were allowed to clot at room temperature and then centrifuged; the serum samples were harvested and frozen at -70°C until assayed.
Urine samples for drug analysis were collected, when feasible, at the following time intervals after the start of the intravenous infusion and after oral dosing: 0 to 2, 2 to 4, 4 to 8, and 8 to 12 h. A portion of each urine collection was stored at -70°C until assayed.
Sample analysis. Serum and urine samples were analyzed by high-performance liquid chromatography (1). The lower limit of assay sensitivity was 5 ng/ml, and the interday and intraday assay coefficients of variation were less than 8% over the concentration range of 10 to 20,000 ng/ml (1).
Datum analysis. The serum-concentration-versus-time profiles of intravenous ciprofloxacin were fit to an open, linear, two-compartment model with zero order input and first order transfer and output by using an iterative, nonlinear, unweighted, least squares regression technique (18) .
The data were fit by using a multiple dose model utilizing the Nelder-Mead simplex algorithm (18) . The following pharmacokinetic parameters were calculated by using the computerfitted estimates of the y intercepts, R and S, and the disposition rate constants, a and ,: transfer rate constants (k12 and k21), overall elimination rate constant (k1o), distribution and elimination half-lives (t4/2. and t,2,3, respectively), volume of the central compartment (V1), and beta-phase volume of distribution (V.) (10) Table 1 . Nine patients participated in the intravenous pharmacokinetic evaluation; six patients also participated in the oral pharmacokinetic evaluation. The reasons for dropping out of the study before completion were clinical failure in three patients (patients 7, 8, and 9). Estimated creatinine clearances did not change significantly between the two study phases (7).
Oral and intravenous ciprofloxacin therapy was well tolerated by the patients. No adverse reactions with probable or highly probable relationship to drug administration were observed.
Pharmacokinetics. Ciprofloxacin serum-concentrationversus-time profiles were evaluated after intravenous and oral administration. Immediately after a 1-h 200-mg intravenous infusion, the mean (± standard deviation) ciprofloxacin concentration in serum was 3.5 ± 0.8 ptg/ml; at 11 h after the end of the infusion, the mean drug concentration in serum (Cmin) had fallen to 0.4 ± 0.3 ,ug/ml. The mean Cm. of 7.6 + 2.2 ,ug/ml occurred 1.9 ± 1.0 h after oral administration, and the Cmin at 12 h after oral dosing was 1.6 + 0.8 ,ug/ml.
The pharmacokinetic parameters after intravenous and oral dosing at steady state are summarized in Table 2 . After intravenous ciprofloxacin administration, mean CLs, CLR, and Vss were 4.38 ± 1.80 ml/min per kg, 2.49 ± 1.52 ml/min per kg (n = 4), and 1.6 ± 0.6 liters/kg, respectively. The tl/2. and tl/2,1 were 0.31 ± 0.18 and 5.8 + 2.4 h, respectively.
After oral ciprofloxacin administration, Tg averaged 0.4 + 0.5 h, indicating a wide interpatient variability. The mean absolute oral bioavailability averaged 77.7 ± 24.2% in the six patients completing both intravenous and oral pharmacokinetic assessments.
Steady-state ciprofloxacin serum-concentration-versustime profiles after intravenous and oral administration are illustrated in Fig. 1 for the six patients participating in both study phases.
DISCUSSION
Compared with data derived from studies of young adult volunteers receiving single doses of intravenous ciprofloxacin (4, 5, 8, 13, 20) , CLs, CLR, and V., were decreased in our study patients. In addition, the mean Cm. in the elderly patients was almost twofold greater after multiple dose oral therapy compared with data obtained in young adult volunteers receiving the same doses (7.6 ± 2.2 versus 4.15 ± 0.72 ,ug/ml), and the mean Tm. in elderly patients was slightly increased (1.9 ± 1.0 versus 1.39 ± 0.55 h) (11) . The variability in Tm. and T1., may have been due to our inability to delay breakfast sufficiently or to interrupt continuous tube feeding in some patients, possibly resulting in delayed absorption (17) .
The presence of acute infection, however, does not appear to be associated with altered ciprofloxacin pharmacokinetics in the elderly. Our data are in agreement with previously published reports that Cm., CLs/F, CLR, and VjS/F in our patient population are significantly altered (2, 3, 15) . Pharmacokinetic data from acutely ill elderly patients receiving multiple oral doses of ciprofloxacin also suggested that the presence of infection was associated with no significant pharmacokinetic alterations (12). The bioavailability of ciprofloxacin was 77.7 ± 24.2%, slightly higher and more variable than that reported previously in normal volunteers after single dose assessment (the range was approximately 52 to 77%) (5, 8, 13, 20) . Possible explanations include drug ingestion proximate to mealtimes, administration concomitant with continuous tube feedings, concurrent administration with drugs altering gastric motility or acidity, or decreased first-pass hepatic metabolism. Administration of single and multiple dose oral ciprofloxacin with food to normal volunteers, however, has been reported to decrease AUC (2) or delay absorption without other alterations in pharmacokinetics (17) . Therefore, food interactions may not explain the increased F. Because elderly patients frequently require treatment with multiple medica- tions, the effects of concomitant administration of vitamins, laxatives, prednisone, and other medications on ciprofloxacin disposition may warrant further study.
Ciprofloxacin concentrations in serum after oral dosing with 750 mg every 12 h were substantially higher than after intravenous dosing with 200 mg every 12 h. Although ciprofloxacin penetrates well into lung tissue (19) , anatomical, physicochemical, and host factors also play a role in determining the ability of antibiotics to achieve bactericidal concentrations in the lung. The MIC of ciprofloxacin for 90% of strains of Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, Enterobacter spp., and Haemophilus influenzae ranges between 0.008 and 0.25 gg/ml (6) . However, the ranges of ciprofloxacin MICs for 90% of strains tested are higher against Pseudomonas aeruginosa, Streptococcus pneumoniae, and Staphylococcus aureus: 0.12 to 1, 1 to 4, and 0.12 to 1 ,xg/ml, respectively (6) 
